Erschienen in:
01.06.2013 | Case Report
Two CML patients who subsequently developed features of essential thrombocythemia with JAK2-V617F mutation while in complete cytogenetic remission after treatment with imatinib mesylate
verfasst von:
Yoo Jin Lee, Joon Ho Moon, Ho Cheol Shin, Jong Won Seo, Seo Ae Han, Sang Kyeong Seo, Sang Kyun Sohn
Erschienen in:
International Journal of Hematology
|
Ausgabe 6/2013
Einloggen, um Zugang zu erhalten
Abstract
The present report describes two chronic myelogenous leukemia (CML) patients with the JAK2-V617F mutation who were in complete hematologic and cytogenetic remission and subsequently developed clinical features of essential thrombocythemia under treatment with tyrosine kinase inhibitors. In light of the findings from previous reports, screening for the JAK2-V617F mutation should be considered for any Ph+ CML patients with thrombocytosis, leukocytosis, or erythrocytosis at diagnosis and for patients who subsequently develop thrombocytosis, leukocytosis, or erythrocytosis during follow-up, even for CML patients in complete cytogenetic response and major molecular response.